Genetics 360º

Proprietary devices

Compact analyser architectures developed for automated molecular testing in professional point-of-care and near-patient settings.

Microfluidic reaction cards

Proprietary disposable reaction-card formats integrate fluid handling, reaction chambers and optical readout interfaces for multiplex nucleic-acid testing.

Assay and primer design

In-house molecular-biology capabilities support isothermal assay development, multiplex optimisation and mutation-specific amplification for infectious-disease and oncology applications.

Data analysis

Real-time amplification monitoring and structured analytical workflows support assay evaluation, optimisation and development documentation.

AI-enabled development

Digital and AI-assisted workflows identify, screen and rank candidate primer sets before wet-lab validation, with the objective of reducing design iterations and accelerating time to a viable assay.

News

Genomtec in numbers

10+
years. Developing molecular-diagnostics technologies since 2016.
20
granted patents. A growing international patent portfolio protecting core elements of Genomtec technology.
35+
pending applications. Additional patent applications across multiple jurisdictions and technology families.
1st
integrated platform. One development framework spanning analyser hardware, reaction cards, assays, optical detection, software and AI-enabled design

What makes us unique

Integrated, defensible technology portfolio

A broad intellectual-property portfolio covers key elements of amplification chemistry, analyser architecture, microfluidic reaction cards, optical readout and AI-assisted assay-development workflows.

AI-enabled assay development

Proprietary digital workflows support target selection, primer screening, secondary-structure assessment and candidate ranking before wet-lab validation.

Engineering and industrialisation capability

Genomtec combines molecular biology with analyser, microfluidic-card and systems engineering, while advancing design control, beta-system readiness and manufacturing scale-up.

Development-stage diagnostic programmes

Current programmes include rapid respiratory and STI panels for the Genomtec ID platform and an automated liquid-biopsy system for Companion diagnostics (CDx) – OncoSNAAT.

Team statement – intentionally unchanged

Exclusive team has significant technical and commercial experience

European development base

Based in Wroclaw, Poland, Genomtec operates within the European medical-technology ecosystem and works with international development, manufacturing and commercial partners.

See more

Services & partnership areas

Integration of Genomtec amplification, reaction-card, optical-heating, detection or software components into partner-developed diagnostic solutions

Joint development of assays, cartridges and analyser workflows for defined professional-use diagnostic applications

Design, screening and experimental optimisation of isothermal amplification assays, including multiplex and mutation-specific applications

Licensing models for selected Genomtec intellectual property, know-how, assay designs and platform components, structured for defined fields and territories

Structured collaboration with diagnostic companies, healthcare sites and distributors to generate product evidence, evaluate beta systems and prepare market-entry pathways

Application of AI-assisted and in-silico workflows to accelerate target identification, primer selection, assay optimisation and development documentation
See more

Markets we serve

Life Sciences

$88B today
11.75% CAGR

Clinical Diagnostics

$86B today
6% CAGR

Food Safey

$25B today
7% CAGR

Veterinary

$8B today
9.75% CAGR

Pets

$3.6B today
9% CAGR

Bio Security

$5.5B today
13% CAGR

See more

Awards

Maker in China

Genomtec took third place in the 2020.

Comeptition directly supported by the China-CEEC SME Research Institute Government Organisation, in which over 300 companies from Central and Eastern Europe and China compete. Genomtec ID is attracting the attention of Chinese investors, and the company is reassured that its efforts will be backed by the Chinese government’s anticipated expansion in that market at the local and central level.

China Shenzhen Innovation & Entrepreneurship

In November 2020 Genomtec took second place in the 4th edition.

Genomtec took second place in the 4th edition of the international competition and received an award of RMB 650,000 RMB, which is about PLN 400,000. Its innovative Genomtec ID platform beat out international competition with 1,046 projects entered. This win opens up new business and development opportunities on the Chinese market for the Company.

Next Health Investment Pitch

Genomtec took 1st place in May 2019.

Genomtec wins the competition organised for Polish companies who want to define economic reality through their innovations via Amgen and ImpactCEE. Amgen has been an international pioneer in biotechnology since 1980 and one of the world leaders in the production of biological medicines.

Start Up Med

Genomtec took 1st place in March 2019.

Genomtec won competition organised by the 4th Health Challenges Congress, a forum for a multi-topic discussion on key issues for healthcare systems in Europe.

Wszystkie nagrody